BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Glenmark Pharma (GNP) delivered in-line 4QFY23 operational performance. GNP witnessed robust traction in Europe/RoW/API segment, driving 20% YoY growth in EBITDA for the quarter. The increased working capital requirement for EU/ROW markets has resulted in higher net debt on a QoQ basis.
We raise our EPS estimate for FY24/FY25 by 3%/5% to factor in a) increase in Ryaltris sales across multiple markets and expansion into newer markets, b) reduced innovative R&D expenses, and c) superior execution in the UK, Spain, and ROW markets. We value GNP at 12x 12M forward earnings to arrive at a price target of INR580.
GNP is making efforts toward a) enhancing domestic formulation (DF) segment prospects through new launches, b) gaining market share as well as adding newer markets in the RoW/EU segment and c) resolving regulatory issues at Monroe/Goa/Baddi. However, we reiterate our Neutral stance as the current valuation adequately factors the upside in the earnings.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
